We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ubrogepant in the Acute Management of Migraine: A Narrative Review.
- Authors
Chiang, Chia-Chun; VanderPluym, Juliana H
- Abstract
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. The ACHIEVE I and ACHIEVE II Phase III clinical trials showed that ubrogepant was superior to placebo for pain freedom and freedom of the most bothersome migraine-associated symptom at 2 hours after medication intake. The 52-week open label extension of the Phase III trials demonstrated safety of ubrogepant. A real-world study conducted at a tertiary headache center also confirmed the efficacy and safety of ubrogepant. Adverse event rates were higher in the real-world population. Studies are needed to evaluate its long-term efficacy and safety, especially in the setting of co-administration with other CGRP modulating therapies such as the CGRP monoclonal antibodies.
- Subjects
UNITED States. Food &; Drug Administration; CALCITONIN gene-related peptide; MIGRAINE; MIGRAINE aura; PRIMARY headache disorders; MONOCLONAL antibodies; ADULTS
- Publication
Journal of Pain Research, 2021, Vol 14, p1185
- ISSN
1178-7090
- Publication type
Article
- DOI
10.2147/JPR.S244249